• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study
CONCLUSION: As first-line agents, SGLT2 inhibitors and GLP1 receptor agonists would improve type 2 diabetes outcomes, but their costs would need to fall by at least 70% to be cost-effective.PRIMARY FUNDING SOURCE: American Diabetes Association.PMID:36191315 | DOI:10.7326/M21-2941
Source: Annals of Internal Medicine - October 3, 2022 Category: Internal Medicine Authors: Jin G Choi Aaron N Winn M Reza Skandari Melissa I Franco Erin M Staab Jason Alexander Wen Wan Mengqi Zhu Elbert S Huang Louis Philipson Neda Laiteerapong Source Type: research

Sodium-Glucose Cotransporter-2 Inhibitors Versus Glucagon-like Peptide-1 Receptor Agonists and the Risk for Cardiovascular Outcomes in Routine Care Patients With Diabetes Across Categories of Cardiovascular Disease
CONCLUSION: Use of SGLT2 inhibitors versus GLP-1 RAs was associated with consistent reductions in HHF risk among T2D patients with and without CVD, although the absolute benefit was greater in patients with CVD. There were no large differences in risk for MI or stroke among T2D patients with and without CVD.PRIMARY FUNDING SOURCE: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School.PMID:34570599 | DOI:10.7326/M21-0893
Source: Annals of Internal Medicine - September 27, 2021 Category: Internal Medicine Authors: Elisabetta Patorno Phyo T Htoo Robert J Glynn Sebastian Schneeweiss Deborah J Wexler Ajinkya Pawar Lily G Bessette Kristyn Chin Brendan M Everett Seoyoung C Kim Source Type: research

Comparative efficacy of 5 sodium glucose cotransporter 2 inhibitor and 7 glucagon-like peptide 1 receptor agonists interventions on cardiorenal outcomes in type 2 diabetes patients: A network meta-analysis based on cardiovascular or renal outcome trials
Conclusions: This updated network meta-analysis reproduced the findings in the first network meta-analysis, and moreover revealed that sotagliflozin was one of the most effective drugs as for lowering MI, stroke, MACE, and HHF, whereas ertugliflozin was not. These findings will provide the according evidence regarding the usage of specific SGLT2 inhibitors and GLP-1 RAs in T2D patients for prevention of specific cardiorenal endpoints.
Source: Medicine - July 30, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Effects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes: A meta-analysis with trial sequential analysis
Conclusions: Compared with placebo, SGLT2 inhibitors conclusively reduce the risk of MACE, CVD or HHF, ACD, CVD, HHF, and KFP in patients with type 2 diabetes, whereas the effects of SGLT2 inhibitors on MI and stroke are not conclusive and need to be further assessed in future studies with the adequate sample size to reject or accept the effect size.
Source: Medicine - March 12, 2021 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

Sodium ‐glucose co‐transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician
ConclusionsSGLT2 inhibitors are an exciting addition to the list of available agents for T2DM, and may be suitable for various types of patients who need additional glycaemic control.
Source: International Journal of Clinical Practice - March 1, 2017 Category: Internal Medicine Authors: Paresh Dandona, Ajay Chaudhuri Tags: REVIEW ARTICLE Source Type: research